Bright Minds Biosciences Inc. (DRUG)
DRUG Stock Price Chart
Explore Bright Minds Biosciences Inc. interactive price chart. Choose custom timeframes to analyze DRUG price movements and trends.
DRUG Company Profile
Discover essential business fundamentals and corporate details for Bright Minds Biosciences Inc. (DRUG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Mar 2021
Employees
26.00
Website
https://brightmindsbio.comCEO
Ian McDonald
Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
DRUG Financial Timeline
Browse a chronological timeline of Bright Minds Biosciences Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$1.28.
Earnings released on 20 May 2026
EPS came in at -$0.80 surpassing the estimated -$1.06 by +24.48%.
Earnings released on 12 Feb 2026
EPS came in at -$0.70 surpassing the estimated -$0.98 by +28.57%.
Earnings released on 23 Dec 2025
EPS came in at -$0.41 surpassing the estimated -$0.56 by +27.13%.
Earnings released on 14 Aug 2025
EPS came in at -$0.53 surpassing the estimated -$0.59 by +10.17%.
Earnings released on 13 Feb 2025
EPS came in at $0.01 surpassing the estimated -$0.23 by +104.35%.
Earnings released on 30 Dec 2024
EPS came in at -$0.12 surpassing the estimated -$0.44 by +72.94%.
Earnings released on 14 Aug 2024
EPS came in at $0.04 .
Earnings released on 15 May 2024
EPS came in at -$0.10 .
Earnings released on 12 Feb 2024
EPS came in at -$0.32 .
Earnings released on 29 Dec 2023
EPS came in at -$0.30 .
Earnings released on 14 Aug 2023
EPS came in at -$0.29 .
Stock split effective on 14 Jul 2023
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2023
EPS came in at -$0.08 .
Earnings released on 7 Feb 2023
EPS came in at -$0.10 .
Earnings released on 29 Dec 2022
EPS came in at -$0.15 .
Earnings released on 12 Aug 2022
EPS came in at -$0.87 .
Earnings released on 16 May 2022
EPS came in at -$1.51 .
Earnings released on 14 Feb 2022
EPS came in at -$1.61 .
Earnings released on 29 Dec 2021
EPS came in at -$0.24 .
DRUG Stock Performance
Access detailed DRUG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
